Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates

Financial Performance - Lineage Cell reported a quarterly loss of $0.02 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of $0.04 per share a year ago [1] - The company posted revenues of $1.5 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 31.73%, but showing a slight increase from $1.44 million year-over-year [2] - Over the last four quarters, Lineage Cell has surpassed consensus EPS estimates three times and has topped consensus revenue estimates three times as well [2][1] Stock Performance - Lineage Cell shares have declined approximately 4.7% since the beginning of the year, compared to a decline of 0.6% for the S&P 500 [3] - The current Zacks Rank for Lineage Cell is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.02 on revenues of $2.25 million, and for the current fiscal year, it is -$0.07 on revenues of $16.05 million [7] - The trend of estimate revisions for Lineage Cell is mixed, which could change following the recent earnings report [6] Industry Context - Lineage Cell operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the top 35% of over 250 Zacks industries [8] - Research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]